Support: 888-992-3836
|
NewsWire
|
Home
|
Login / Register
Boards
Stocks
Commodities
Forex
Cryptocurrency
The Lounge
Hot!
Breakout Boards
Follow Feed
iHub My Stocks Activity
Ticker Buzz Cloud
Most Read
Most Posted
Most Followed Members
Recent News
News By Market
Active Boards
Site Stats
New Boards
Cannabis Stocks
Top PlusOneCoin Posters
Tools
Data Tools >
Charts
Trader Alerts
Trades
Portfolio
Top Lists
Price & News Alerts
Commodities
NewsWire
More Tools >
Newsletters
InvestorsHub Daily
My Image Gallery
Advanced Search
Videos
All News
Stock Screener
News Filter
Live Charts
Live News
Live Desktop
Forex Prices
Commodities
ETF Center
Educational Channel
Follow Feed
News Scanner
Crypto
Top Cryptocurrencies
PLUS1 Info & Faucet
Top Tokens
New Cryptocurrencies
Mining Profit Calculator
Crypto Converter
Streamer
Level 2
Home
>
Boards
>
US OTC
>
Biotechs
>
Oxford BioMedica PLC (OXBDF)
Add OXBDF Price Alert
Hide Sticky
Hide Intro
Moderator:
Search This Board:
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003+
Last Post:
2/10/2021 10:37:12 PM
-
Followers:
7
- Board type:
Free
- Posts Today:
0
Oxford BioMedica PLC (OXBDF)
Trades In UK as (OXB.L)
Company website
UK company traded on grey's in US
Company Address:
Medawar Centre
Robert Robinson Avenue
Oxford, OX4 4GA
United Kingdom -
Map
Phone: 44 18 6578 3000
Fax: 44 18 6578 3001
Oxford BioMedica plc
, a biopharmaceutical company, develops gene-based medicines and therapeutic vaccines for the treatment of cancer, and age-related or inherited neurodegenerative disorders and ocular diseases. Its LentiVector gene delivery technology platform targets non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes. The company is developing ProSavin, which has completed Phase I/II trials for the treatment of Parkinson's disease; RetinoStat that is in Phase I trial for ?wet? age-related macular degeneration; StarGen, which is in Phase I/IIa trial for the treatment of Stargardt disease; UshStat that is in Phase I/IIa trial for Usher syndrome type 1B; EncorStat, which is Phase I/II trial preparation for the prevention of corneal graft rejection; and Glaucoma-GT, which is in pre-clinical stage for the treatment of chronic glaucoma. It is also developing TroVax that is in Phase II trial for colorectal cancer and mesothelioma; and Anti-5T4 antibody, which is in pre-clinical stage for the treatment of cancer. In addition, the company is developing MoNuDin for the treatment of motor neuron disease. It has collaborations and licensing agreements with Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, and ImaginAb. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
Management
Partnerships
Financial Reports:
http://www.oxfordbiomedica.co.uk/financial-reports/
Investor Contacts:
http://www.oxfordbiomedica.co.uk/investor-contacts/
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock.
Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:
http://investorshub.advfn.com/boards/complex_terms.asp
OXBDF
Current Price
Volume:
Bid
Ask
Day's Range
OXBDF Detailed Quote
1D
1M
2M
3M
6M
1Y
2Y
3Y
5Y
Post New Msg
Follow Board
My Stocks (0)
Hide Intro
View Posters
OXBDF Poststream
Bans (0)
Hide Quote
Filter Disabled
Post
Subject
#805
WHO expert group recommends use of AstraZeneca vaccine
georgejjl
02/10/21 10:37:12 PM
#804
AstraZeneca’s (Oxford BioMedica's) vaccine is poised to become
georgejjl
02/05/21 01:00:33 PM
#803
WHP completes viral vector manufacturing centre for Oxford Biomedica
georgejjl
12/30/20 08:59:28 PM
#802
Oxford Biomedica notes AstraZeneca’s COVID-19 vaccine has been
georgejjl
12/30/20 08:56:50 PM
#801
John Dawson named Executive of the Year for
georgejjl
12/03/20 09:50:02 PM
#800
FDA allows AstraZeneca’s COVID-19 vaccine trial to resume
georgejjl
10/25/20 08:13:34 PM
#799
Oxford University Covid-19 vaccine trials resume
georgejjl
09/13/20 08:21:48 PM
#798
Oxford Biomedica Signs Supply Agreement with AstraZeneca to
georgejjl
09/01/20 12:41:56 PM
#797
Oxford coronavirus vaccine induces strong immune response
georgejjl
07/20/20 02:08:22 PM
#796
Safety and Immunogenicity of Novel 5T4 Viral Vectored
georgejjl
07/09/20 05:54:57 PM
#795
Oxford Biomedica snags manufacturing equipment to ramp up
georgejjl
06/26/20 09:43:19 PM
#794
AstraZeneca agrees to make COVID-19 vaccine for Europe
georgejjl
06/13/20 01:03:59 PM
#793
AstraZeneca Approaches Gilead About Potential Merger
georgejjl
06/07/20 01:37:54 PM
#792
AstraZeneca is aiming to produce 2 billion doses
georgejjl
06/04/20 04:17:46 PM
#791
AstraZeneca locks up COVID-19 vaccine supply with Oxford
georgejjl
05/28/20 07:27:11 PM
#790
Oxford Biomedica Signs Clinical & Commercial Supply Agreement
georgejjl
05/28/20 09:03:10 AM
#789
The Oxford COVID-19 vaccine is 'progressing very well,'
georgejjl
05/22/20 07:34:28 PM
#788
U.S. to invest $1.2 billion to secure potential
georgejjl
05/21/20 05:13:10 PM
#787
U.S. to invest $1.2 billion to secure potential
georgejjl
05/21/20 05:12:34 PM
#786
AstraZeneca Aims for 30 Million U.K. Vaccine Doses
georgejjl
05/17/20 10:06:12 PM
#785
HTTps://www.youtube.com/watch?v=-sGNsKpmB-c
marcusl2
05/17/20 08:26:14 AM
#784
Nine Ten Capital Management LLC Buys , Oxford
marcusl2
05/17/20 08:24:14 AM
#783
Monkey trial of Oxford vaccine shows encouraging results
georgejjl
05/15/20 11:37:11 PM
#782
In April the Group has joined a Consortium
georgejjl
05/15/20 09:13:02 PM
#781
Oxford Biomedica bags MHRA nod for two manufacturing suites
georgejjl
05/13/20 08:30:45 PM
#780
John Dawson, Chief Executive Officer of Oxford Biomedica, said:
marcusl2
05/13/20 04:06:05 AM
#779
Emily Whitehead past, present and FUTURE
georgejjl
05/09/20 12:13:14 PM
#778
Oxford scientist says its vaccine is making headway,
georgejjl
05/03/20 05:32:23 PM
#777
Bill Gates says the world would need as
georgejjl
05/03/20 09:13:02 AM
#776
Coronavirus vaccine update: How far along is the
georgejjl
05/02/20 07:50:10 AM
#775
Bill Gates says the world will need 7
georgejjl
04/30/20 07:39:58 PM
#774
The Jenner Institute at Oxford University made the
georgejjl
04/30/20 07:16:41 PM
#773
AstraZeneca enters deal to manufacture University of Oxford's
georgejjl
04/30/20 06:11:42 PM
#772
In Race for a Coronavirus Vaccine, an Oxford
georgejjl
04/28/20 07:48:13 PM
#771
Good News on Oxford Vaccine Is Bright Spot
georgejjl
04/28/20 07:42:30 PM
#770
6 monkeys given an experimental coronavirus vaccine from
georgejjl
04/28/20 01:27:18 PM
#769
University of Oxford coronavirus vaccine trial aims to
georgejjl
04/17/20 04:30:05 PM
#768
The COVID 19 trial with ChAdOx1 nCov-19
georgejjl
04/08/20 10:29:43 PM
#767
https://www.edisongroup.com/wp-content/uploads/2020/04/Oxford-BioMedica-Juno-dea
marcusl2
04/08/20 04:32:53 PM
#766
Oxford Biomedica joins Consortium to rapidly develop a
georgejjl
04/08/20 06:54:06 AM
#765
AXO-Lenti-PD http://investors.axovant.com/static-files/986b7b10-3d28-4afc-947
georgejjl
03/30/20 08:38:32 PM
#764
AXO-Lenti-PD delivers a 22-point (44%) improvement from baseline
marcusl2
02/23/20 04:29:46 AM
#763
British scientists accidentally discover immune cell that 'may
georgejjl
01/23/20 07:55:02 AM
#762
Harnessing the immune system to fight cancer could
georgejjl
01/22/20 08:28:16 PM
#761
Immune discovery 'may treat all cancer'
georgejjl
01/20/20 11:24:48 PM
#760
Gene Therapy for Parkinson's Disease: Preclinical Evaluation of
georgejjl
01/05/20 01:46:39 PM
#759
https://www.evaluate.com/vantage/articles/analysis/plenty-choice-remains-buyers-
marcusl2
12/21/19 09:45:43 AM
#758
Oxford Biomedica PLC
marcusl2
12/19/19 08:59:31 AM
#757
AXO-Lenti-PD http://investors.axovant.com/static-files/b6b0cded-8d58-46d4-99a
georgejjl
12/03/19 09:54:40 PM
#756
Novartis's $90 million Swiss factory to help solve
georgejjl
11/29/19 06:19:25 PM
Post
Subject
Post New Msg
Follow Board
My Stocks (0)
Hide Intro
View Posters
OXBDF Poststream
Bans (0)
Hide Quote
Filter Disabled
Balance Available:
0
Get FREE PlusOneCoins!
© 2021 InvestorsHub.com, Inc.
Consent Preferences